Relaxin activates the L-arginine-nitric oxide pathway in human breast cancer cells
- PMID: 7585587
Relaxin activates the L-arginine-nitric oxide pathway in human breast cancer cells
Abstract
Recently, we demonstrated that relaxin (RLX), a peptide hormone of ovarian origin, inhibits growth and promotes differentiation of MCF-7 breast adenocarcinoma cells. We also showed that RLX stimulates the production of nitric oxide (NO) in several cell types. NO has been reported to have antitumor activity by inhibiting proliferation, promoting differentiation, and reducing the metastatic spread of some tumor cell types. In this study, we aimed at evaluating whether RLX influences the L-arginine-NO pathway in MCF-7 cells. The cells were grown in the absence or presence of RLX at different concentrations, and cell proliferation, constitutive and inducible NO synthase activities, nitrite production, and intracellular levels of cyclic GMP were investigated. The results obtained indicate that RLX increases inducible NO synthase activity and potentiates NO production. This was accompanied by an elevation of intracellular cyclic GMP, which is known to mediate the cell response to NO. The RLX-induced activation of the L-arginine-NO pathway in the MCF-7 cells was inversely related to the rate of cell proliferation. These results suggest that the cytostatic effect of RLX on MCF-7 breast cancer cells may rely on its ability to stimulate endogenous production of NO.
Similar articles
-
Relaxin and breast cancer.Bull Cancer. 1997 Feb;84(2):179-82. Bull Cancer. 1997. PMID: 9180842
-
Relaxin up-regulates inducible nitric oxide synthase expression and nitric oxide generation in rat coronary endothelial cells.FASEB J. 2002 Feb;16(2):252-4. doi: 10.1096/fj.01-0569fje. Epub 2001 Dec 14. FASEB J. 2002. PMID: 11744624
-
Relaxin depresses platelet aggregation: in vitro studies on isolated human and rabbit platelets.Lab Invest. 1995 Nov;73(5):709-16. Lab Invest. 1995. PMID: 7474945
-
The role of nitric oxide in L-arginine-stimulated growth hormone release.J Endocrinol Invest. 1999;22(5 Suppl):89-93. J Endocrinol Invest. 1999. PMID: 10442577 Review.
-
Relaxin and nitric oxide signalling.Curr Protein Pept Sci. 2008 Dec;9(6):638-45. doi: 10.2174/138920308786733921. Curr Protein Pept Sci. 2008. PMID: 19075752 Review.
Cited by
-
Tissue-specific relaxin-2 is differentially associated with the presence/size of an arterial aneurysm and the severity of atherosclerotic disease in humans.Acta Pharmacol Sin. 2020 Jun;41(6):745-752. doi: 10.1038/s41401-019-0350-5. Epub 2020 Feb 5. Acta Pharmacol Sin. 2020. PMID: 32024951 Free PMC article.
-
Immunoexpression of the relaxin receptor LGR7 in breast and uterine tissues of humans and primates.Reprod Biol Endocrinol. 2003 Nov 24;1:114. doi: 10.1186/1477-7827-1-114. Reprod Biol Endocrinol. 2003. PMID: 14633277 Free PMC article.
-
Enhanced serelaxin signalling in co-cultures of human primary endothelial and smooth muscle cells.Br J Pharmacol. 2016 Feb;173(3):484-96. doi: 10.1111/bph.13371. Epub 2016 Jan 15. Br J Pharmacol. 2016. PMID: 26493539 Free PMC article.
-
Role of myoepithelial cells in breast tumor progression.Front Biosci (Landmark Ed). 2010 Jan 1;15(1):226-36. doi: 10.2741/3617. Front Biosci (Landmark Ed). 2010. PMID: 20036817 Free PMC article. Review.
-
Temperature-dependent studies of NO recombination to heme and heme proteins.J Am Chem Soc. 2005 Dec 7;127(48):16921-34. doi: 10.1021/ja054249y. J Am Chem Soc. 2005. PMID: 16316238 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical